2025 Agenda
*All times are in EST
Apr
Fri 11
Welcome Reception
Bay Lawn
Apr
Sat 12
Breakfast & Registration
Welcome & introduction
Gareth Morgan & Ola Landgren
Session 1: Genomics and epigenomics 2025
Chairs: Gareth Morgan & Leif Bergsagel
- The genetic basis for racial disparity in MM: Kylee MacLachlan
- The transcriptional mechanism of action of NSD2: Yubao Wang
- Apoptotic profiling of t(4:14) MM: Lawrence Boise
- Epigenetic features of t(4;14) MM: Benjamin Barwick
- The genetic basis and origin of MM: Francesco Maura
- Structural variation in MM in depth analysis of PDX model: Brian Walker
- Whole arm structural abnormalities: Aneta Mikulesova
Panel discussion: Using genomic targets in MM
Break
Session 2: Resistance mechanisms
Chairs: Benjamin Diamond & Niels Weinhold
- Tumor intrinsic resistance mechanisms to immunotherapy: Michael Durante
- Lenalidomide resistance: Charlotte Pawlyn
- Transcriptional resistance and MM as a superenhanceropathy: Leif Bergsagel
- Focal and breakout lesions in the evolution of resistance: Niels Wienhold
- Biallelic antigen escape is a recurrent mechanism of resistance to anti-CD38 antibodies: Ben Diamond
Panel discussion: addressing drug resistance
Session 3: Biological models and single cell analyses
Chairs: Charlotte Pawlyn & Felipe Prósper
- Novel insights from the Vk*MYC mouse model: Marta Chesi
- Modeling MM genetic and immune heterogeneity in nice: José Ángel Martínez–Climent
- Complex human bone marrow organoids for the study of MM: Sarah Gooding
- Epigenetic drivers of disease progression: Felipe Prósper
- Genomic profiling of Precursor Disease; Bachisio Ziccheddu
- Immune microenvironment and resistance to therapy: Madhav Dhodapkar
Panel discussion: future strategies for myeloma management
Lunch
Session 4: Update on MRD as a clinical endpoint
Chairs: Ola Landgren
Panel discussion
Session 5: Clinical trial updates
Chairs: Adriana Rossi & Rafael Fonseca
- Emerging approaches for use of bispecific antibodies in precursors: Ola Landgren
- The emerging role of belantamab mafodotin: Rafael Fonseca
- Efficacy and safety of isatuximab combinations frontline and at relapse MM: Thomas Martin
- Daratumamab combinations their current and future role: Dickran Kazandjian
Panel discussion: questions for clinical trials
Break
Session 6: MMRF Update
Chairs: George Mulligan & Hearn Cho
- The HORIZON Adaptive trial platform: Nitya Nathwani
- Translational studies of the MyDrug trial MEKi arm: Chuck Acharya
- Tumor and microenvironment insights from Immune Atlas: Reyka Jayasinghe
Panel Discussion
Closing remarks
Apr
Sun 13
Welcome and Introductions
Keynote Lecture
Chair: Niels Weinhold
The spatio-temporal evolution of multiple myeloma: Leo Rasche
Panel discussion
Session 7: Novel Targets
Chairs: Faith Davies & Arun Wita
- The role of allogeneic BCMA-targeting CAR-T cells in RRMM: Sham Mailankody
- Novel approaches to targeting RAS as a potential clinical therapy: Faith Davies
- CAR T cells targeting novel membrane-based antigens: Arun Wita
- Novel biomarkers for guiding the use of immunotherapies: Frank Zhan
Panel discussion: developing novel targets for the clinic
Break
Session 8: Optimizing T-Cell Engaging therapy in the clinic: data session
Part 1: Bispecifics
Chairs: Damian Green & Yi Lin
Overview lecture:
Novel resistance mechanisms for bispecific antibodies in MM: Nizar Bahlis
- The current and future use of teclistamab: Saad Usmani
- The current use and development of talquetamab; Ciara Freeman
- Update on the clinical data using elranatamab; Nizar Bahlis
- Progress on the clinical data using elranatamab; Nizar Bahlis
- Optimizing BCMA as a therapeutic target; Damian Green
Panel discussion: Optimizing the use of Bispecifics in the clinic
Lunch
Part 2: CAR-T
Chairs: Adam Cohen & Ciara Freeman
- The development and application of ADC for use in MM: Hans Lee
- Developing the use and application of the current licenced Car T cell therapies: Adam Cohen
- The development and potential of Anito-cel; Matthew J. Frigault
- Update on the use of allogeneic anti-BCMA CAR-T CB-011: Adriana Rossi
- Exploiting innovative CAR-T designs and targets: Yi Lin
Panel discussion: Optimizing the use of CAR-T in the clinic
Summary & closing remarks of iwMyeloma 2025
Gareth Morgan & Ola Landgren
iwMyeloma Scientific Committee:
Gareth Morgan (Co-Chair) USA, Ola Landgren (Co-Chair) USA
Ken Anderson USA, Leif Bergsagel USA, Irene Ghobrial USA, Sagar Lonial USA, Maria Victoria Mateos Spain, Jesus San Miguel Spain, Pieter Sonneveld NL, Keith Stewart Canada